CAMBRIDGE, Mass.--(BUSINESS WIRE)--Iterative Health, a pioneer in precision-medicine technologies for gastroenterology, announced today that it has partnered with Gastro Health, a national leading medical group specializing in digestive and liver health, to bring its AI Recruitment (AIR) technology to Gastro Health’s practices. This strategic partnership will lay the groundwork for future collaborations by using AIR to aid in the recruitment of patients for clinical trials in inflammatory bowel disease (IBD) and expanding Gastro Health’s clinical research capabilities.Gastro Health is one of the largest national medical groups specializing in digestive and liver health and has a presence in seven states – Florida, Alabama, Washington, Virginia, Ohio, Maryland, and Massachusetts – with over 380 physicians and 150 locations consisting of medical offices, infusion centers, imaging services, and a specialty pharmacy. Gastro Health owns and operates endoscopy centers as well as pathology and anesthesia services. Iterative Health is a pioneer in the application of advanced artificial intelligence (AI) tools in gastroenterology. To date, the company has raised $195M in funding and is rapidly growing in pursuit of its mission to use computer vision-based technology to reduce disparities in healthcare. Iterative Health has partnered with multiple clinical research sites and continues to expand its impact and reach through this relationship with Gastro Health.“ Our shared mission with Iterative Health to democratize access to the highest quality GI care has opened the door for us to utilize AIR in our practices,” said Joseph Garcia, CEO of Gastro Health

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Iterative Scopes, a pioneer in precision-medicine technologies for gastroenterology, announced today that it has partnered with One GI®, a gastroenterology management services organization (MSO), to bring its AI Recruitment (AIR) technology to One GI’s clinical research. Initially, One GI® will use AIR at Gastro One, one of One GI’s clinical research sites in Memphis, Tennessee, with plans to expand to additional research sites within the One GI® network. The implementation of AIR will aid in the recruitment of patients for clinical trials focused on inflammatory bowel disease (IBD). Both One GI® and Iterative Scopes are fast-growing innovators in the gastroenterology space. One GI® is a unique, rapidly expanding MSO that brings together community-based practices, including Gastro One, a network of six practices across Tennessee. The MSO currently has 40 sites within its network across Tennessee, Mississippi, Kentucky, Ohio, and Indiana. Iterative Scopes is a pioneer in the application of powerful, proprietary artificial intelligence tools to the practice of gastroenterology and drug development

Annual list recognizes innovators and leaders in life-sciences who positively impact the industry at large. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Iterative Scopes, a pioneer in precision-medicine technologies for gastroenterology, announced today that Jonathan Ng, MBBS, the company’s founder and CEO, has been named to the PharmaVoice 100 — an annual list that recognizes the most inspiring people in the life-sciences industry